Omalizumab, the first available antibody for biological treatment of severe asthma: more than a decade of real-life effectiveness
Omalizumab was the first, and for a long time the only available monoclonal antibody for the add-on treatment of severe allergic asthma. In particular, omalizumab selectively targets human immunoglobulin (Ig)E, forming small-size immune complexes that inhibit IgE binding to its high- and low-affinit...
|Main Authors:||, , , , ,|
|Series:||Therapeutic Advances in Respiratory Disease|